Which antipsychotic medication is known for being a potent mood stabilizer and treating resistant Major Depressive Disorder (MDD) and schizophrenia?

The medication recognized for its potent mood stabilizing properties and effectiveness in treating resistant Major Depressive Disorder (MDD) and schizophrenia is Brexpiprazole (Rexulti). This atypical antipsychotic functions by modulating neurotransmitter systems, particularly by acting on dopamine D2 and serotonergic 5-HT1A receptors, which helps in improving mood and alleviating depressive symptoms while also providing antipsychotic effects beneficial in schizophrenia.

Brexpiprazole is noted for its lower side effects profile compared to some other antipsychotic medications. Its use in resistant cases of MDD is supported by clinical trials demonstrating its efficacy as an adjunctive treatment, making it a valuable option for patients who do not respond well to traditional antidepressant therapies.

In contrast, other medications listed may have mood stabilizing effects but are not primarily celebrated for their efficacy in this dual role of treating resistant depression alongside schizophrenia. For example, while Olanzapine and Quetiapine are effective antipsychotics and carry mood-stabilizing characteristics, they are not as primarily recommended for resistant MDD as Brexpiprazole. Cariprazine is also effective in schizophrenia and bipolar disorder but does not carry the same level of evidence